文献速递白血病MDS 与骨髓增殖性肿瘤

基于患者特异性基因组标记监测急性髓系白血病及髓系恶性肿瘤的可测量残留病

Patient-specific genomic measurable residual disease markers for monitoring acute myeloid leukaemia and myeloid malignancy.
PubMed 文献 · Br J Haematol · 2026-10-20

该研究利用RNA-seq、靶向NGS或WGS数据开发患者特异性PCR-MRD检测,在97.6%的患者中成功建立检测,并对40例髓系恶性肿瘤患者进行前瞻性PCR-MRD监测。髓系MRD报告周转时间与ALL MRD相似,50%的髓系恶性肿瘤患者具有定量范围≤5×10^-5的MRD标记,高于ALL患者的29%。系列MRD监测与疾病结局相关,两名孤立性中枢神经系统复发患者在髓外复发时骨髓有低水平受累。

要点

  • 基于NGS/WGS可为难治性AML患者开发患者特异性PCR-MRD检测。
  • 髓系恶性肿瘤患者中具有高灵敏度MRD标记的比例高于ALL患者。
  • 系列PCR-MRD监测与疾病结局相关,可指导临床决策。

核心结论

  • 基于基因组数据开发的患者特异性PCR-MRD检测在多数髓系恶性肿瘤患者中可行,且与疾病结局相关。

研究设计与样本

  • 利用RNA-seq、靶向NGS或WGS数据开发患者特异性PCR-MRD检测,按EuroMRD指南报告。
  • 在97.6%的患者中成功建立PCR-MRD检测,并对40例髓系恶性肿瘤患者进行前瞻性监测。

主要发现

  • 髓系MRD报告周转时间与ALL MRD相似。
  • 50%的髓系恶性肿瘤患者具有定量范围≤5×10^-5的MRD标记,高于ALL患者的29%。
  • 具有两个MRD标记的患者中,检测间一致性极好。
  • 系列MRD监测与疾病结局相关。
  • 两名孤立性中枢神经系统复发患者在髓外复发时骨髓有低水平受累。

关键数值与推荐

  • 髓系恶性肿瘤患者中50%具有定量范围≤5×10^-5的MRD标记,ALL患者为29%。

临床怎么用

  • 患者特异性PCR-MRD可用于髓系恶性肿瘤的监测,尤其适用于缺乏标准流式或RNA-PCR靶点的患者。
  • 建议在经验丰富的MRD实验室按照EuroMRD标准化指南开展前瞻性临床试验进一步研究。

局限性

  • 研究样本量较小(40例患者),需更大规模前瞻性临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) has improved acute lymphoblastic leukaemia (ALL) outcomes. Applying acute myeloid leukaemia (AML) MRD has been limited due to complexity identifying leukaemia-specific targets. Current AML MRD relies on flow cytometry or ribonucleic acid (RNA)-based quantitative polymerase chain reaction (PCR) but cannot be applied to all patients. With next-generation or whole genome sequencing (NGS/WGS), myeloid MRD targets can be identified, suggesting that DNA-based PCR-MRD could be used. Genomic data including RNA-seq, targeted NGS or WGS were used to develop patient-specific PCR-MRD assays, which were reported using EuroMRD guidelines. We developed PCR-MRD assays in 97.6% patients and conducted prospective PCR-MRD monitoring in 40 myeloid malignancy patients. Myeloid MRD reports had a similar turnaround time to ALL MRD. Myeloid MRD markers were highly sensitive with a higher proportion of myeloid malignancy patients (50%) having an MRD marker with a quantitative range of ≤5 × 10-5 compared to ALL patients (29%). In patients with two MRD markers, there was excellent inter-assay concordance. Serial MRD correlated with disease outcome. Two patients with isolated CNS relapse had low-level BM involvement at extra-medullary relapse. Myeloid malignancy PCR-MRD should be studied prospectively in clinical trials across experienced MRD laboratories using the standardised EuroMRD guidelines.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Huang L, Doculara L, Enriquez L, et al. Patient-specific genomic measurable residual disease markers for monitoring acute myeloid leukaemia and myeloid malignancy. Br J Haematol. 2026. PMID: 42902921. doi:10.1111/bjh.70880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。